Hepatopancreatobiliary Carcinoma

In Capan-1 cell lines engineered to reduce pRB expression (by transfection with p16), resensitization to chemotherapy-induced apoptosis was observed. The effect was asserted to be specific to pRB depl… (full text at CIViC)

PMID 11792751 · Plath et al., 2002 · Open in CIViC

Surgically resected PDACs were used to create tissue microarrays, which were scored for antibody staining of hENT1 (SLC29A1). For patients treated with gemcitabine (n=243), high levels of hENT1 were a… (full text at CIViC)

PMID 22705007 · Maréchal et al., 2012 · Open in CIViC

In this case report of a single patient with pancreatic adenocarcinoma was found to harbour a SLC4A4::ROS1 fusion by NGS analysis. Based on the presence of the ROS1 fusion the patient was initiated on… (full text at CIViC)

PMID 37079858 · Reutter et al., 2023 · Open in CIViC

In 249 patients that have undergone a pancreaticoduodenectomy (Whipple) for the resection of pancreatic ductal adenocarcinoma, expression of SMAD4 is associated with favorable prognosis. SMAD4 was ass… (full text at CIViC)

PMID 11751510 · Tascilar et al., 2001 · Open in CIViC

In a study of 89 patients with adenocarcinoma of the pancreas who underwent a pancreaticoduodenectomy, those with mutations in SMAD4 had shorter overall survival than wild-type patients.

PMID 19584151 · Blackford et al., 2009 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

Phase 2 trial of adult hepatocellular patients treated with sunitinib analyzed how baseline concentration of different soluble VEGF proteins predict overall survival (OS) and time to progression (TTP)… (full text at CIViC)

PMID 21787417 · Harmon et al., 2011 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR.

PMID 29466156 · Drilon et al., 2018 · Open in CIViC